4/27
10:22 am
rhhby
PSG Report Finds Cost Management Remains Payers' Top Goal as Coverage Strategy for New Drugs and Indications Emerges as Biggest Specialty Drug Management Challenge [Yahoo! Finance]
Low
Report
PSG Report Finds Cost Management Remains Payers' Top Goal as Coverage Strategy for New Drugs and Indications Emerges as Biggest Specialty Drug Management Challenge [Yahoo! Finance]
4/24
09:00 am
rhhby
Roche (RHHBY) was upgraded by Morgan Stanley from "underweight" to "equal weight". They now have a $46.00 price target on the stock.
Low
Report
Roche (RHHBY) was upgraded by Morgan Stanley from "underweight" to "equal weight". They now have a $46.00 price target on the stock.
4/24
08:47 am
rhhby
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME' Campaign [Yahoo! Finance]
Low
Report
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME' Campaign [Yahoo! Finance]
4/24
08:00 am
rhhby
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign
Low
Report
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign
4/23
06:36 pm
rhhby
Roche Holding AG (RHHBY) Q1 2026 Sales/Trading Call Transcript [Seeking Alpha]
Low
Report
Roche Holding AG (RHHBY) Q1 2026 Sales/Trading Call Transcript [Seeking Alpha]
4/23
07:32 am
rhhby
LiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor [Yahoo! Finance]
Low
Report
LiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor [Yahoo! Finance]
4/23
04:13 am
rhhby
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment [MSNBC.com]
Low
Report
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment [MSNBC.com]
4/23
03:13 am
rhhby
Roche sales slip in Q1 as strong franc weighs [Yahoo! Finance]
Low
Report
Roche sales slip in Q1 as strong franc weighs [Yahoo! Finance]
4/22
03:23 pm
rhhby
Roche Holding (SWX:ROP) Valuation In Focus After Mixed Short And Long Term Returns [Yahoo! Finance]
Low
Report
Roche Holding (SWX:ROP) Valuation In Focus After Mixed Short And Long Term Returns [Yahoo! Finance]
4/22
09:18 am
rhhby
Flatiron Health Announces 18 Research Acceptances Featuring Flatiron's Real-World Data to Be Presented at ISPOR 2026 [Yahoo! Finance]
Low
Report
Flatiron Health Announces 18 Research Acceptances Featuring Flatiron's Real-World Data to Be Presented at ISPOR 2026 [Yahoo! Finance]
4/22
09:00 am
rhhby
Flatiron Health Announces 18 Research Acceptances Featuring Flatiron's Real-World Data to Be Presented at ISPOR 2026
Low
Report
Flatiron Health Announces 18 Research Acceptances Featuring Flatiron's Real-World Data to Be Presented at ISPOR 2026
4/21
07:27 pm
rhhby
Genentech's Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS [Yahoo! Finance]
Low
Report
Genentech's Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS [Yahoo! Finance]
4/21
07:15 pm
rhhby
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
Low
Report
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
4/21
12:06 pm
rhhby
Genentech's Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD [Yahoo! Finance]
Low
Report
Genentech's Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD [Yahoo! Finance]
4/21
11:45 am
rhhby
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
Low
Report
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
4/21
06:13 am
rhhby
Healthy diets spark lung cancer risk in non-smokers as pesticides loom [FOX News]
High
Report
Healthy diets spark lung cancer risk in non-smokers as pesticides loom [FOX News]
4/21
01:48 am
rhhby
FDA Accepts Application for Genentech's Gazyva for the Treatment of the Most Common Form of Lupus [Yahoo! Finance]
High
Report
FDA Accepts Application for Genentech's Gazyva for the Treatment of the Most Common Form of Lupus [Yahoo! Finance]
4/21
01:00 am
rhhby
FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
High
Report
FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
4/20
09:00 am
rhhby
Flatiron Health Publishes First Peer-Reviewed Validation Framework for AI-Extracted Real-World Oncology Data in Journal of Clinical Oncology
Low
Report
Flatiron Health Publishes First Peer-Reviewed Validation Framework for AI-Extracted Real-World Oncology Data in Journal of Clinical Oncology
4/16
07:43 am
rhhby
Roche launches new Elevidys study after feedback from European regulator [Yahoo! Finance]
Low
Report
Roche launches new Elevidys study after feedback from European regulator [Yahoo! Finance]
4/16
07:00 am
rhhby
Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform
Low
Report
Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform
4/13
07:16 pm
rhhby
Is Chugai Pharmaceutical (TSE:4519) Still Attractively Priced After Its Strong Multi Year Run [Yahoo! Finance]
Low
Report
Is Chugai Pharmaceutical (TSE:4519) Still Attractively Priced After Its Strong Multi Year Run [Yahoo! Finance]
4/9
01:30 pm
rhhby
Eli Lilly Launches Foundayo: A Novel Oral GLP-1 Weight Management Therapy [TheStreet.com]
Low
Report
Eli Lilly Launches Foundayo: A Novel Oral GLP-1 Weight Management Therapy [TheStreet.com]
4/9
08:15 am
rhhby
C4 Therapeutics inks new deal with Roche for degrader-antibody conjugates [Seeking Alpha]
Low
Report
C4 Therapeutics inks new deal with Roche for degrader-antibody conjugates [Seeking Alpha]
4/6
06:05 pm
rhhby
Two more pharmaceutical companies, Abbvie and Genentech, to officially launch on TrumpRx [CBS News]
Low
Report
Two more pharmaceutical companies, Abbvie and Genentech, to officially launch on TrumpRx [CBS News]